BREATHOX® is a safe and effective expectorant indicated in enhancement of mucociliary clearance, and in the alleviation of nasal and bronchial congestion.
The treatment is non-medical and based on salt particle inhalation.
BREATHOX® improves quality of life for consumers by improving and maintaining their ability to breathe more comfortably.
Technology
Breathox® is the worlds first salt particle inhaler*.
The patented breath-actuated device allows the consumer to use the product comfortably at home or on-the-go.
The Sodium Chloride ingredient is based on salt directly extracted from a 280 million year old salt tectonic in Northern Denmark. Subsequently, this raw material is processed into pharmaceutical grade NaCl complying with the monographs of all int. pharmacopoeia; Ph. Eur., USP, JP, KP, Ph. Rus. This unique technology makes the Breathox an unprecedented, drug-free offer to consumers with respiratory challenges.
Breathox® is developed by a team of leading Scandinavian scientist, designers and engineers.
*) The dispensed NaCl micro particle size range from 1-10µm allowing respiratory application.
Market
Breathox® is an OTC product targeted at the following consumer segments:
- chronic or temporary respiratory patients
- allergy sufferers
- smokers and ex-smokers
Together these segments consist of more than 25% of the international OTC market.
